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Abstract
Learning to read and write the transcriptional regulatory code is of central importance to progress
in genetic analysis and engineering. Here, we describe a massively parallel reporter assay (MPRA)
that enables systematic dissection of transcriptional regulatory elements by integrating microarray-
based DNA synthesis and high-throughput tag sequencing. We apply MPRA to compare more
than 27,000 distinct variants of two inducible enhancers in human cells: a synthetic cAMP-
regulated enhancer and the virus-inducible interferon beta enhancer. We first show that the
resulting data define accurate maps of functional transcription factor binding sites in both
enhancers at single-nucleotide resolution. We then use the data to train quantitative sequence-
activity models (QSAMs) of the two enhancers. We show that QSAMs from two cellular states
can be combined to identify novel enhancer variants that optimize potentially conflicting
objectives, such as maximizing induced activity while minimizing basal activity.
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INTRODUCTION
Genetic analysis and engineering would greatly benefit from an improved understanding of
how transcriptional regulatory elements are encoded in DNA. Evolutionary analysis and
chromatin-state mapping have revealed myriad regulatory elements across the human
genome1–2, but we are largely unable to explain why an element is active in a specific cell
type or to predict the effect of a specific mutation. Moreover, synthetic regulatory elements
can provide powerful tools for genetics, high-throughput screening and gene therapy3–5, but
our ability to engineer such elements is similarly limited - particularly in mammalian
systems, where traditional functional assays6 suffer from low throughput and directed
evolution is generally impractical.
To enable systematic dissection and optimization of transcriptional regulatory elements, we
developed a massively parallel reporter assay (MPRA; Fig. 1). MPRA is similar in principle
to the in vitro transcription-based assay of ref. 7, but is suitable for use with mammalian
cells. Briefly, we first synthesize tens of thousands of oligonucleotides8 that contain a
library of regulatory elements, each coupled to a short tag. We use the oligonucleotides to
generate a pool of plasmids, where each plasmid contains one of the regulatory elements, an
optional invariant promoter, an arbitrary open reading frame (ORF) and an identifying
sequence tag. We co-transfect these plasmids into cells, where active elements drive
transcription of mRNAs containing the tags in their 3' UTRs. To estimate their relative
activities, we sequence and count the tags in the reporter mRNAs and the plasmids pools,
and then take the ratios of these counts. The resulting data is amenable to a variety of
analyses, including high-resolution footprinting and quantitative modeling9.
As a proof of concept, we applied MPRA to study two inducible enhancers: a synthetic
cAMP-regulated enhancer (CRE), which is widely used as a cellular cAMP sensor4, and the
virus-inducible enhancer of the human interferon beta (IFNB) gene, which is one of the most
comprehensively studied mammalian regulatory elements10. These sequences represent two
different enhancer architectures11. The synthetic CRE is a “billboard” enhancer that contains
multiple non-overlapping binding sites for the cAMP-responsive transcription factor CREB.
In contrast, the IFNB enhancer contains overlapping binding sites for six different
transcription factors that assemble into a highly cooperative “enhanceosome”.
In this report, we first establish that MPRA can accurately identify functional sequence
features in both enhancers at nucleotide resolution. Next, we use MPRA data to train
quantitative sequence-activity models (QSAM)9,12–13 that describe the activity of the
enhancers in their induced or uninduced states. Finally, we demonstrate that these QSAMs
can be combined to identify mutations that increase enhancer inducibility (the ratio of
induced versus uninduced activity).
RESULTS
Experimental design and mutagenesis strategies
We synthesized 142mer oligonucleotide pools containing 87 nt CRE and INFB enhancer
variants, as well as 10 nt tags and various invariant sequences required for cloning
(Supplementary Fig. 1).
We tested two different mutagenesis strategies. The first was a “single-hit scanning”
strategy7 where we assayed ~1,000 specific enhancer variants, including all possible single
substitutions, multiple series of consecutive substitutions, and small insertions at all
positions (Supplementary Table 1). Each scanning variant was linked to 13 tags for a total of
13,000 distinct enhancer-tag combinations. This redundancy provides parallel measurements
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for each variant, which can be used to both quantify and to reduce the impact of
experimental noise, including tag-dependent bias (Supplementary Fig. 2). The second was a
“multi-hit sampling” strategy9 where we assayed ~27,000 distinct enhancer variants
(Supplementary Table 2), each linked to a single tag. These variants were constructed by
introducing random nucleotide substitutions into the enhancers at a rate of 10% per position.
Because the variants were designed in silico and then synthesized, they provide a uniform
mutational spectrum. This strategy has the advantages that each substitution is assayed in a
larger fraction of the variants and that the use of multiple substitutions enables detection of
interactions; a disadvantage is less accurate measurements for individual variants.
We cloned oligonucleotide pools synthesized according to both strategies into identical
plasmid backbones, inserted a minimal TATA-box promoter and a luciferase gene between
the variants and tags, and transfected the resulting plasmid pools into human embryonic
kidney (HEK293T) cells. To induce the CRE or IFNB enhancer, we treated the transfected
cells with forskolin or infected them with Sendai virus, respectively. To estimate the relative
activities of the enhancer variants, we sequenced 20–120 million PCR-amplified mRNA and
plasmid tags from each transfection.
Assay validation
We validated the resulting data using several different approaches (Supplementary Fig. 3).
First, we examined the distributions of plasmid tag counts. We found that the vast majority
(≥99.6%) of the tags we designed were indeed present in each pool, and that their relative
concentrations were similar (coefficient of variation = 0.45–1.0). This confirms successful
generation of high complexity plasmid pools.
Second, we synthesized and transfected each of the two CRE plasmid pools twice. We found
that the ~13,000 and ~27,000 pairs of mRNA/plasmid tag ratios obtained from the single-
and multi-hit pools, respectively, were highly correlated (Pearson r2 = 0.61 and 0.67, least
significant p < 10−100). The medians of the 13 tag ratios from each distinct variant in the
replicate single-hit pools were even more similar (r2 = 0.89, p < 10−100). This indicates that
MPRA is robust, and that the noise level can be controlled by adjusting the number of
distinct tags linked to each distinct variant.
Finally, we subcloned 24 plasmids from each of two CRE pools and individually measured
their luciferase expression levels following forskolin treatment. We found a linear
relationship between the MPRA- and luciferase-based activities for both pools (r2 = 0.45 and
0.75, p < 0.0002). This indicates that MPRA is directly comparable to traditional reporter
assays.
Single-hit scanning
We began our analysis by attempting to dissect the two induced enhancers using the
scanning mutagenesis data. We estimated the relative activity of each variant by comparing
the median of its 13 mRNA/plasmid tag ratios to the median ratio for tags linked to the
corresponding “wild-type” enhancer7.
We first focused on the CRE, which contains two consensus CREB dimer binding sites
(denoted as sites 1 and 4 in Fig. 2a) separated by two monomer sites (sites 2 and 3). We
found that 154 of the 261 possible single substitutions significantly altered its activity (5%
FDR), with the majority (79%) resulting in decreased activity (Fig. 2b). The substitutions
that resulted in the largest decreases were in or immediately flanking the CREB sites.
Substitutions in the promoter-proximal CREB site 4 had the largest effects, which is
consistent with reports of the cAMP-responsiveness of CREB sites being inversely
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correlated with their distance to a TATA-box14. Within the two dimer sites, substitutions in
the central CGs were the most deleterious. This is consistent with biochemical data that
show that this dinucleotide is critical for high affinity CREB-DNA interactions15.
Substitutions at 47 of 61 positions outside of the CREB sites also caused significant,
although generally more subtle, changes in activity. This may reflect the effects of cryptic
non-CREB binding sites. In particular, two substitutions upstream of CREB site 1, as well as
almost every substitution in a C-rich motif flanking CREB site 4, resulted in increased CRE
activity. These substitutions may therefore cause either increased recruitment of activating
factors or decreased recruitment of repressors.
Scanning the CRE with blocks of eight consecutive substitutions caused changes that were
consistent with the single substitutions, but often more deleterious (Fig. 2c; Supplementary
Fig. 4). Notably, while most single substitutions in CREB site 1 had no detectable effects,
this site was clearly identified by the introduction of multiple substitutions.
Insertions of both 5 and 10 nucleotides were well-tolerated at multiple positions between
CREB sites 1 and 2 and between sites 3 and 4 (Fig. 2d; Supplementary Fig. 5). This implies
that the CRE activity is not dependent on specific spacing or phasing between these sites. In
contrast, insertions between sites 2 and 3 resulted in decreased activity, despite single
substitutions having small effects in the same region. This may reflect a direct interaction
between proteins at these two sites, which was also suggested by a study of these sites in
their natural context16.
We next focused on the IFNB enhancer, which is a 44 nt sequence containing overlapping,
non-consensus binding sites for an ATF-2/c-Jun heterodimer, two IRF-3 and two IRF-7
proteins, and a p50/RELA (NF-κB) heterodimer (Fig. 3a)10. We included a small amount of
flanking genomic sequence, for a total length of 87 nt. We found that 83 of the 261 possible
single substitutions altered its activity in virus-infected cells (5% FDR), and that almost all
(92%) of these were within the 44 nt core (Fig. 3b). Scanning with consecutive substitutions
did not reveal any unambiguously functional sequences outside of this core (Fig. 3c;
Supplementary Fig. 6).
Within the core, there were only nine positions where all alternate nucleotides could be
introduced without affecting its activity. Strikingly, seven of these positions were in gaps
between the 5′- and 3′-halves of IRF sites, where these proteins primarily interact with the
DNA backbone10. Insertions were also largely deleterious within the core (Fig. 3d;
Supplementary Fig. 7). Both 5 and 10 nt insertions were, however, tolerated between IRF-7
site 2 and the p50/RELA site, which is consistent with the absence of a known protein or
interaction spanning this gap.
Finally, seven single substitutions within the core caused a significant increase in activity.
At least four of these would be predicted to increase the affinity of a protein-DNA
interaction, by introducing a central CG into the ATF-2/c-Jun site (TGACATAG to
TGACGTAG), changing the 3′-halves of IRF-3 site 1 or 2 to its consensus (AAAA or
GAGA to GAAA) or changing the NF-κB 5′ half-site to a sequence specifically preferred
by the p50 subunit (GGGAA to GGGGA)17. We note that introduction of such consensus
sites are, however, likely to decrease the specificity of the enhancer towards viral infection
(see below and ref. 18).
Multi-hit information footprints
We next attempted to dissect the two enhancers using the multi-hit sampling data9. To
quantify the dependency between enhancer activity and substitutions at a specific position,
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we estimated the mutual information between the nucleotides at that position and the
corresponding tag ratios across the ~27,000 variants. To infer the effect of substitutions on
the basal enhancer activities, we also assayed the variants in untreated cells. The resulting
“information footprints”9,19 are shown in Figures 4 and 5.
We found that the 27 most informative positions in the induced CRE footprint were all
located in or immediately flanking the four CREB sites (Fig. 4a). The more symmetric
footprint of dimeric CREB site 4 compared to site 1 likely reflects the palindromic flanks of
the former (ATTGACGTCAAT vs. AGTGACGTCAGC). The information contents of
CREB sites 2–4 were substantially lower in the uninduced state, which is consistent with
cAMP-dependence. In contrast, the information contents of CREB site 1 and the cryptic
binding sites near CREB sites 1 and 4 were higher in the uninduced footprint. This is again
consistent with the most promoter-distal CREB site being less cAMP-dependent14 and
suggests that these sites may be important for controlling the basal CRE activity.
The IFNB enhancer footprint from virus-infected cells shows, as expected, that its
functionally relevant nucleotides are concentrated in the 44 nt core (Fig. 5a). Indeed, 35 of
46 positions that had significant information content (5% FDR) are located in the core.
Strikingly, the uninduced IFNB footprint revealed only 8 informative positions, compared to
73 in the uninduced CRE footprint. This likely reflects the very low basal activity of the
IFNB enhancer (at least 5-fold lower than the uninduced CRE in luciferase assays).
Quantitative sequence-activity models
We next attempted to develop QSAMs9,12–13 for the two enhancers, with the goal of
predicting the activity of novel variants. As a first step, we used linear regression to train
QSAMs where each nucleotide position is simply assumed to contribute additively to the
log-transformed activity of the enhancers in the induced or uninduced states12–13.
Linear QSAMs trained on the multi-hit data are shown in Figures 4b and 5b (see
Supplementary Figs. 8 and 9 for models trained on single-hit data). Inspection revealed good
qualitative correspondence with the sequence features described above. For example, the
two CRE models show that CREB site 1 is critical for maximizing the induced activity,
while site 4 has the largest influence on the basal activity.
To quantify how well the linear models describe our data, we compared their predictions to
the observed activities for both the ~27,000 variants in the multi-hit training sets and the 261
single substitutions in the independent single-hit data. For the CRE, we found that the linear
model for the induced state generates predictions that are highly correlated with the
observed activities of both multi- and single-hit variants (r2 = 0.63, p < 10−100 and r2 = 0.79,
p < 10−89, respectively). Remarkably, this model therefore explains ~90% of the non-
technical variance in both data sets (compare to r2 = 0.67 and 0.89 between replicates, see
above). The large number of multi-hit measurements ensures that this is not the result of
over-fitting (r2 ≥ 0.62 on five-fold cross-validation). In contrast, the induced IFNB model
performed significantly better on single-hit variants (r2 = 0.61, p < 10−54) than on multi-hit
variants (r2 = 0.071, p < 10−100), despite being trained on the latter set.
The difference in the fit of linear models appears to reflect the different architectures of the
enhancers. Most CRE multi-hit variants disrupt one or more of the non-overlapping
consensus CREB sites, which caused large (median = 4.7-fold) and roughly additive
reductions in its induced activity, until an apparent minimum is reached (Supplementary Fig.
8b). Multiple substitutions in the induced IFNB enhancer generally caused weaker (median
= 1.8-fold) and non-additive reductions in activity, which may reflect its initially weaker
non-consensus binding sites or more complex interactions between its transcription factors.
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Since both enhancers showed evidence of nonlinear responses, we next attempted to refine
our QSAMs by incorporating functional nonlinearities. We fit a variety of QSAMs to the
data, including ones describing either dinucleotide interactions or biophysical interactions
between DNA-bound proteins (Supplementary Notes, Supplementary Tables 5 and 6).
Model parameters were optimized using linear regression or mutual information
maximization9. For the CRE, the best performing QSAM was a “linear-nonlinear” model20
in which each nucleotide position is assumed to contribute additively to a linear activation
measure, and a sigmoidal function of that measure then gives the transcriptional response.
The optimal parameters for the linear part of this model are virtually identical (r2 = 0.98) to
the strictly linear QSAM, but the two additional parameters that describe the sigmoidal
nonlinearity allow the model to describe both minimum and maximum activation levels.
Interestingly, this nonlinearity appears to capture much of the remaining non-technical
variance in the induced CRE data (r2 = 0.72, p < 10−100, compared to r2 = 0.67 between the
two replicates). For the IFNB enhancer, the best performing models were those that
incorporated dinucleotide interactions, which is consistent with its more complex
architecture, although no model provided more than a modest improvement over the linear
QSAM (up to r2 = 0.10, p < 10−100). Thus, while linear QSAMs are imperfect
representations of the underlying biological systems, in these cases they appear to provide a
reasonable trade-off between complexity and predictive power.
Model-based optimization
Linear QSAMs have previously proven useful for engineering regulatory elements in
bacteria12,21. To explore the potential for model-based optimization of synthetic regulatory
elements in mammals, we next attempted to design enhancers with modified activities.
We first attempted a “greedy” approach to maximize the induced enhancer activities. We
selected, for each position, the nucleotide predicted to make the largest activity contribution
according to the corresponding linear model. This resulted in changing the CRE at 36 of 87
positions (CRE-A1 in Fig. 6a). These changes left the consensus CREB sites intact, but
introduced predicted activating mutations into the flanks of CREB sites 1–3 and into the two
cryptic binding sites. For the IFNB enhancer, we limited modifications to the 44 nt core.
This resulted in changes at 15 positions (IFNB-A1 in Fig. 6c) including conversion of every
non-consensus IRF half-site to the GAAA consensus and strengthening the p50 half-site. We
individually synthesized these two variants and then compared them to their “wild-types”
using a luciferase assay. We found that both new variants had significantly higher induced
activities (2.1-fold for CRE-A1 and 2.6-fold for IFNB-A1; Fig. 6b, d). Interestingly, the
increase for CRE-A1 (2.1-fold) was substantially lower than predicted by the simple linear
model (32-fold), but close to the value predicted by the linear-nonlinear model (1.7-fold). In
contrast, the increase for IFNB-A1 (2.6-fold) was close to the value predicted by its linear
model (2.1-fold). This difference likely reflects that the wild-type CRE is composed of
consensus activator sites and therefore operates much closer to saturation than the IFNB
enhancer. We also found, however, that both new variants had disproportionately higher
uninduced activities (19-fold for CRE-A1 and 17-fold for IFNB-A1). This suggests that
mutations that increase the induced activity of an enhancer may often decrease its
inducibility, which would likely be detrimental in most biological and engineering contexts.
Accordingly, we attempted instead to maximize the inducibility of the two enhancers. We
simultaneously considered the induced and uninduced linear QSAMs and, for each position,
selected the nucleotide predicted to maximize inducibility, without (1) increasing the
uninduced activity or (2) decreasing the induced activity relative to the wild-type. For the
CRE, we synthesized three variants (CRE-I1 to -I3 in Fig. 6a). CRE-I1 and -I2 were
predicted by QSAMs trained on each of the two replicate CRE data sets and contained 10
and 12 substitutions. CRE-I3 contained only the five substitutions that were shared between
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the first two. Only one variant (CRE-I2) contained any activating substitutions in the cryptic
motifs near CREB sites 1 and 4. We found that all three variants showed a significant
increase in induced activity without the large decrease in inducibility seen for CRE-A1 (Fig
6b). Moreover, CRE-I3 showed no increase in uninduced activity, which resulted in a ~25%
increase in inducibility relative to the wild-type (~44-fold vs. ~35-fold). Notably, we failed
to isolate variants with similar or higher inducibilities from the original random variants
(Supplementary Fig. 10). For the IFNB enhancer, we synthesized one variant containing five
substitutions in the core, none of which modified the non-consensus sites (IFNB-I1 in Fig.
6c). This variant also showed increased inducibility relative to the wild-type (~100-fold vs.
~67-fold).
DISCUSSION
We have developed a massively parallel reporter assay (MPRA) that enables functional
analysis of transcriptional regulatory elements at significantly higher throughput than
traditional bioluminescence- and fluorescence-based assays. In our initial experiments, we
used MPRA to map functional transcription factor binding sites at single-nucleotide
resolution and to train simple quantitative sequence-activity models. The ability to infer
QSAMs of arbitrary functional form using data similar to ours has been demonstrated in
bacteria9. Applied to mammalian cells, this approach may help elucidate the biophysical
basis of inducible and cell type-specific enhancer activity.
MPRA can be readily adapted to other experimental designs by varying the oligonucleotide
composition, promoter-ORF insert, plasmid backbone or transfected cell types. Advances in
DNA synthesis technology promise to enable analysis of longer elements in the near
future22–23 and transposon- or virus-derived sequences can be included in the backbone to
support genomic integration. We therefore expect that the assay will provide a powerful tool
for screening and dissecting the large variety of regulatory elements that are being identified
by the ENCODE Project1, the NIH Roadmap Program on Epigenomics24 and similar efforts.
Beyond studying variants of naturally-occurring DNA sequences, the flexibility and
decreasing cost of DNA synthesis is enabling development of novel regulatory elements.
Strong synthetic promoters have previously been selected from combinatorial libraries using
FACS25–26. It may be challenging, however, to design direct selection strategies for
elements with more complex characteristics, such as optimal inducibility, dynamic range or
cell type-specificity. Model-based optimization represents an alternative to direct selection.
In this approach, all synthesized elements are first profiled in multiple cell states, with the
resulting data being integrated to identify sequences that optimize complex objectives. This
approach can be applied iteratively, which would be conceptually similar to genetic
algorithm-based optimization27. With the development of more sophisticated mutagenesis
and modeling strategies, we expect that this approach will provide a powerful tool for
synthetic biology.
METHODS
Oligonucleotide library design and synthesis
142mer oligonucleotides were designed to contain, in order, the universal primer site
ACTGGCCGCTTCACTG, an 87 nt variable sequence, Kpnl/Xbal restriction sites
(GGTACCTCTAGA), a 10 nt variable tag sequence and the universal primer site
AGATCGGAAGAGCGTCG (see Supplementary Fig. 1). The “wild-type” CRE sequence
was derived from pGL4.29 (Promega). The wild-type interferon beta enhancer sequence was
derived from the NCBl36/hg18 human genome reference assembly. The enhancer variants
were designed as described in `Experimental design and mutagenesis strategies', and 100
Melnikov et al. Page 7
Nat Biotechnol. Author manuscript; available in PMC 2012 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
distinct wild-type enhancer-tag pairs were included in each scanning pool. The distinct tags
were selected from randomly generated 10 nt sequences, with the following constraints: (1)
must contain all four nucleotides, (2) must not contain a run of more than four identical
nucleotides, (3) must not contain a Kpnl or Xbal restriction site, and (4) must not contain a
known mammalian microRNA seed sequence (obtained from http://www.targetscan.org,
April 2009).
The resulting oligonucleotide libraries were synthesized by Agilent, Inc. as previously
described8. Sanger sequencing of subcloned MPRA plasmids suggested that the synthesis
error rate was 1 in 200–300, with small deletions being the most common failure mode (data
not shown).
Plasmid construction
Oligonucleotide libraries were resuspended in TE 0.1 buffer (10 mM Tris-HCl, 0.1 mM
EDTA, pH 8.0) and amplified using 8–12 cycles of PCR using Phusion High-Fidelity PCR
Master Mix with HF buffer (NEB) and primers ACTGGCCGCTTCACTG and
CGACGCTCTTCCGATCT. The resulting PCR products were size-selected on 4% NuSieve
3:1 agarose gels (Lonza), purified using QIAquick G e l Extraction kits (Qiagen) and re-
amplified with primers GCTAAGGGCCTAACTGGCCGCTTCACTG and
GTTTAAGGCCTCCGAGGCCGACGCTCTTC to add Sfil sites.
To generate the plasmid backbone for the MPRA constructs, the luc2 reporter gene was
removed from pGL4.10[luc2] (Promega) by Hindlll-Xbal digestion. The 5' extension of the
Hindlll site was filled in with Klenow fragment of DNA polymerase I (NEB) and the Xbal
site was eliminated by treatment with Mung Bean nuclease (NEB). The resulting linear
plasmid was self-ligated to generate cloning vector pGL4.10M.
To insert the variable regions into the MRPA vector, purified oligonucleotide PCR products
were digested with Sfil (NEB) and directionally cloned into Sfil digested pGL4.10M using
One Shot® TOP10 Electrocomp™ E. coli cells (Invitrogen). To preserve library complexity,
the efficiency of transformation was maintained at >3×108 cfu/μg. Isolated plasmid pools
were digested with Kpnl/Xbal to cut between the enhancer variants and tags, ligated with the
1.78 kb Kpnl-Xbal fragment of pGL4.23[luc2/minP] (Promega), which contains a minimal
TATA-box promoter and the luc2 ORF, and then transformed into E. coli as described
above. Finally, to remove vector background, the resultant plasmid pools were digested with
Kpnl, size selected on a 1% agarose gel, self-ligated and re-transformed into E. coli.
For validation of QSAM optimized enhancers, each variant was individually synthesized
with the constant flanking sequences CTGGCCTAACTGGCCGCTTCACTG and
GGTACCTGAGCTCGC (IDT). The oligonucleotides were PCR amplified as described
above with primers CTGGCCTAACTGGCC and GCGAGCTCAGGTACC, cloned into
pGL4.24[luc2P/minP] (Promega) using the In-Fusion® PCR Cloning System (Clontech)
and verified by Sanger sequencing prior to transfection.
Cell culture and transfection
HEK293T/17 cells (ATCC CRL-11268) were cultured in DMEM (Mediatech) supplemented
with 10% FBS and L-glutamine/penicillin/streptomycin.
For transfection of a plasmid pool, 4×106 cells were grown to 40–50% confluence in a 10
cm culture dish. Cells were transfected with 10 μg DNA from each plasmid pool in 1 mL
OptiMEM® I Reduced Serum Medium (Invitrogen) using 30 μL Lipofectamine™ LTX and
10 μL Plus Reagent (Invitrogen). The transfection mixtures were removed by media
exchange after 5 hours. After 24 hours, cells transfected with CRE plasmid pools were
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treated for 5 hours with 100 μM forskolin (Sigma) in DMSO (induced state) or an
equivalent volume of DMSO only (uninduced state). Cells transfected with IFNB plasmid
pools were infected with Sendai virus (ATCC VR-907) at an MOI of 10 (induced state) or
mock infected (uninduced state) for 16 hours. Immediately following these treatments, cells
were lysed in RLT buffer (Qiagen) and frozen at −80 °C. Total RNA was isolated from cell
lysates using RNeasy kits (Qiagen).
For transfection of individual validation plasmids, 2.3 ×104 cells were seeded into each well
of 96-well plates. Each well was transfected with 15 μl of Opti-MEM® I Reduced Serum
Medium (Invitrogen) containing 100 ng of luc2 reporter plasmid with CRE- or IFNB-
derived variants and 10 ng of pGL4.73[hRluc/SV40] (Promega) for normalization, 0.25 μL
Lipofectamine™ LTX and 0.1 μL Plus Reagent (Invitrogen). Cell were treated with
forskolin or infected with Sendai virus as described above. Luciferase activities were
measured using Dual-Glo® Luciferase Assay (Promega) and an EnVision 2103 Multilabel
Plate Reader (PerkinElmer).
Tag-Seq
mRNA was extracted from total RNA using MicroPoly(A)Purist™ kits (Ambion) and
treated with DNase I using the Turbo DNA-free™ kit (Ambion). First-strand cDNA was
synthesized from 400–700 ng mRNA using High Capacity RNA-to-cDNA kits (Applied
Biosystems).
Tag-Seq sequencing libraries were generated directly from 12% of a cDNA reaction or 50
ng plasmid DNA by 26 cycle PCR using Pfu Ultra HS DNA polymerase 2× master mix
(Agilent) and primers
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCG
ATCT and
CAAGCAGAAGACGGCATACGAGATXXXXXXXXGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTCGAGGTGCCTAAAGG (where XXXXXXXX is a library-specific
index sequence). The resultant PCR products were size-selected using 2% agarose E-Gel EX
(Invitrogen). The libraries were sequenced in indexed pools of eight, or individually, using
36 nt single-end reads on Illumina HiSeq 2000 instruments.
To infer the tag copy numbers in each Tag-Seq library, all sequence reads were examined,
regardless of their quality scores. If the first ten nucleotides of a read perfectly matched one
of the 13,000 or 27,000 designed tags and the remaining nucleotides matched the expected
upstream MPRA construct sequence, this was counted as one occurrence of that tag. All
reads that did not meet this criterion were discarded. All tags that did not have a count of at
least 20 in every sequenced CRE or IFNB enhancer plasmid pool were also discarded. The
mRNA/plasmid tag ratios were normalized by multiplying by the ratio of the total number of
plasmid and mRNA tag counts from the corresponding Tag-Seq libraries.
Analysis of single-hit scanning variants
To estimate the relative activity of each distinct enhancer variant, the median of its 13
mRNA/plasmid tag ratios were compared to the median of the mRNA/plasmid ratios for
tags linked to the corresponding WT enhancer. To increase the accuracy of this comparison,
65 distinct WT enhancer-tag pairs were included in each pool design. Significant differences
in the median ratios were inferred by applying the Mann-Whitney U-test to all variant-WT
pairs and then applying the Benjamini-Hochberg procedure to identify the 5% false
discovery rate (FDR) threshold28.
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Analysis of multi-hit sampling variants
Information footprints were generated as described in ref. 9. Briefly, the mRNA/plasmid tag
ratios from each transfection experiment were first quantized by partitioning into five
equally sized bins. The mutual information values between the bases at each position and the
quantized activities were then estimated using the Treves-Panzeri limited sample
correction 29:
where bi is the base at the ith position, μ is the quantized activity, f() gives the
corresponding joint and marginal frequency distributions and N is the number of assayed
variants.
Error bars on these values were determined by computing uncorrected mutual information
estimates  for 10,000 random sub-samples that each contained 50% of the
enhancer variants. The uncertainties in I(bi;μ) were computed from the variance of these
estimates:
To identify positions with significant information content, empirical null distributions for
I(bi;μ) were generated from 10,000 random permutations of the mapping between the
quantized activities and the enhancer variants. The probability of the absence of information
at the ith position was estimated as (ni+1)/10,000, where ni is the number of random
permutations for which I(bi;μ) exceeded the original value. The Benjamini-Hochberg
procedure was then applied to identify the 5% FDR threshold28.
Quantitative sequence-activity modeling
The method of ordinary least squares was used to train linear QSAMs of the form
where Abi is the activity contribution of base b at the ith position, and xbi is an indicator
variable that is 1 if the enhancer variant σ contains base b at the ith position and 0 otherwise.
Other models, including nonlinear QSAMS, are described in Supplementary Note 1.
Model-based optimization of the induced activity of each enhancer was performed by
identifying and synthesizing
based on the corresponding linear QSAMs (without interaction terms).
Model-based optimization of the inducibility of each enhancer was performed by identifying
and synthesizing
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based on the corresponding linear QSAMs, with the constraints
where WTi is the base at the ith position of the wild-type enhancer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Overview of MPRA
Oligonucleotides containing enhancer variants coupled to distinguishing tags are first
generated using microarray-based DNA synthesis. The variants and tags are separated by
two common restriction sites (circle/square). The oligonucleotides are PCR amplified from
universal primer sites (not shown) and directionally cloned into a plasmid backbone. An
invariant promoter-ORF segment is then inserted between the variants and tags by double
digestion and directional ligation. The resulting reporter plasmid pool is cotransfected into a
population of cells. The relative regulatory activities of the transfected variants are inferred
by sequencing and counting their corresponding tags from the cellular mRNA and the
transfected plasmid pool. See Supplementary Figure 1 for additional details.
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Figure 2. Single-hit scanning mutagenesis of the cAMP-responsive enhancer
(a) The CRE sequence with known and putative transcription factor binding sites indicated.
(b) Changes in induced activity due to single nucleotide substitutions. Each bar shows the
log-ratio of the median variant and wild-type activity estimates. (c) Changes in induced
activity due to 8 consecutive substitutions. The plot shows the medians of three different
types of substitutions, see Supplementary Fig. 3. Each bar is located at the fourth nucleotide
in the corresponding 8 nt substitution. (d) Changes in induced activity due to 5 nt (top) and
10 nt (bottom) insertions. The plots show the means of two different insertions, see
Supplementary Fig. 4. Each bar is located one nucleotide to the right of the insertion. Error
bars show the first and third quartile. Red indicates a significant change from wild-type
(Mann-Whitney U-test, 5% FDR). Numerical values are provided in Supplementary Table 3.
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Figure 3. Single-hit scanning mutagenesis of the virus-inducible IFNB enhancer
(a) The IFNB enhancer with known transcription factor binding sites indicated. (b) Changes
in induced activity due to single nucleotide substitutions. Each bar shows the log-ratio of the
median variant and wild-type activity estimates. (c) Changes in induced activity due to 8
consecutive substitutions. The plot shows the medians of three different types of
substitutions, see Supplementary Fig. 5. Each bar is located at the fourth nucleotide in the
corresponding 8 nt substitution. (d) Changes in induced activity due to 5 nt (top) and 10 nt
(bottom) insertions. The plots show the means of two different insertions, see
Supplementary Fig. 6. Each bar is located one nucleotide to the right of the insertion. Error
bars show the first and third quartile. Red indicates a significant change from wild-type
(Mann-Whitney U-test, 5% FDR). Numerical values are provided in Supplementary Table 4.
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Figure 4. Multi-hit sampling mutagenesis of the cAMP-responsive enhancer
(a) Information footprints of the CRE in its induced (top) and uninduced (bottom) states.
Red indicates significant information content at the corresponding position (permutation
test, 5% FDR). Error bars show uncertainties inferred from sub-sampling. (b) Visual
representations of linear QSAMs of the CRE in its induced (top) and uninduced (bottom)
states. The color in each entry represents the estimated additive contribution of the
corresponding nucleotide to the log-transformed activity of the enhancer. The matrices are
re-scaled such that the lowest entry in each column is zero and the highest entry anywhere is
one. Both matrices are shown on the same scale. Numerical values are provided in
Supplementary Table 3.
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Figure 5. Multi-hit sampling mutagenesis of the virus-inducible IFNB enhancer
(a) Information footprints of the IFNB enhancer in its induced (top) and uninduced (bottom)
states. Red indicates significant information content at the corresponding position
(permutation test, 5% FDR). Error bars show uncertainties inferred from sub-sampling. (b)
Visual representations of linear QSAMs of the IFNB enhancer in its induced (top) and
uninduced (bottom) states. The color in each entry represents the estimated additive
contribution of the corresponding nucleotide to the log-transformed activity of the enhancer.
The matrices are re-scaled such that the lowest entry in each column is zero and the highest
entry anywhere is one. Both matrices are shown on the same scale. Numerical values are
provided in Supplementary Table 4.
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Figure 6. Model-based optimization
(a) CRE variants predicted to maximize induced activity (A1) or inducibility (I1ȓI3) based
on linear QSAMs trained on multi-hit data. Differences from WT are indicated by red
shading. Darker shading indicates a higher predicted contribution to the change in activity.
(b) Luciferase activity of the wild-type (WT) and optimized CRE variants in untreated and
forskolin-treated cells. (c) Inducibility of the CRE variants in response to cAMP elevation
caused by forskolin treatment. (d) IFNB enhancer variants predicted to maximize induced
activity (A1) or inducibility (I1) based on linear QSAMs trained on multi-hit data. (e)
Luciferase activity of the WT and optimized IFNB enhancer variants in uninfected and
virus-treated cells. (f) Inducibility of the IFNB enhancer variants in response to virus
infection. Blue bars show mean activity across 12 replicates in the induced or uninduced
states. Error bars show standard errors of the means (SE). All statistical comparisons are
relative to WT in the same state; n.s., not significant; *, p ≤ 0.05; ***, p ≤ 0.0001; two-tailed
t-test. Orange bars show the ratio of the corresponding induced and uninduced mean
activities. Error bars show the range from (induced mean - induced SE)/(uninduced mean +
uninduced SE) to (induced mean + induced SE)/(uninduced mean - uninduced SE).
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